Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Secondhand baby pyjamas from Lindex to rent at Hyber

Lindex continues to explore and test new services and business models as part of its circular transformation. The fashion company has previously piloted several initiatives within secondhand and now offers the rental of secondhand baby pyjamas together with Hyber. ‘Through our secondhand take-back programme and previous pilots, we have seen that our baby pyjamas can be sold several times over which is a fine receipt that our focus on longevity pays off. Together with Hyber, we are now doing a test where we combine secondhand and rental. It’s a way for us to broaden our offer and

Havfram Wind doubles fleet with order of second Wind Turbine Installation Vessel

April 18th, 2023 – Oslo, Norway – Havfram Wind has ordered a second state-of-the-art Wind Turbine Installation Vessel (WTIV). The order represents the first optional vessel in the existing shipbuilding contract with CIMC Raffles, and the vessel design will be similar to the first GustoMSC NG20000X Jack-Up vessel currently under construction. The latest battery hybrid drive train technology is incorporated in the design to significantly reduce carbon emissions per installed megawatts (MW) of offshore wind capacity. Delivery will be late Q4, 2025.The NG20000X vessel has the capability of

Zalaris announces their new team for Norseman Xtreme Triathlon 2023

Zalaris, the provider of payroll and HR solutions that simplify work life and support creating sustainable businesses, today announced their new team for Norseman 2023.For the fourth year in a row, Zalaris proudly announces the sponsorship of #teamZalaris for Norseman 2023.   Svenja Mann, Torsten Neufeld, Anders Spilling, Sophie Buer, Stanisław Kłęk, Agnieszka Lasyk, Richard Traynor, Mark Bamford, Simone Kragh Jacobsen from Germany, Norway, Poland, the United Kingdom, and Denmark will form the team and will take part in the extreme

Medicover’s socially sustainable commercial paper listed on Nasdaq Stockholm

On 13 April 2023, Medicover launched a Socially Sustainable Commercial Paper Programme under its Social Finance Framework. On 18 April 2023, the commercial paper will be admitted to trading on Nasdaq Stockholm, segment STO Sustainable Commercial Paper.“Social sustainability composes the core of how we operate and invest in healthcare and health. Through the launch and listing of our socially sustainable commercial paper, we are broadening our financing in a way that reflects our business and will be important as we continue to work for better health in the markets we operate”, says Fredrik

Invitation to UPM’s webcast and press conference on Q1 2023 Interim Report

(UPM, Helsinki, 18 April 2023 at 10:00 EEST) – UPM will publish its Q1 2023 Interim Report on 25 April 2023 at 09:30-10:00 EEST. After publishing, the report will be available on the company website at www.upm.com . A webcast and a conference call for analysts and investors in English begins at 13:15 EEST. The interim report will be presented by the President and CEO Jussi Pesonen and CFO Tapio Korpeinen. Participants can view the webcast online through this link , but participants who wish to ask questions

BIBB informs about the status of the CE marking process according to MDR

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), which develops and manufactures a new type of electric-driven endoscopic biopsy instrument, EndoDrill[®], hereby provides a status update on the CE mark approval process of the product portfolio EndoDrill[®]. In summary, after discussions with BiBB's notified body, the Company expects a CE certificate according to MDR in approximately 3–6 months. The upcoming CE certificate according to MDR means an extended indication and includes all three instruments in the product family EndoDrill[®].At the turn of the year

Invitation to the presentation of Ratos Interim report January-March 2023

The Interim report January-March 2023 will be released on Thursday 27 April at 07.00 CEST.At 09.00 CEST will Jonas Wiström, President and CEO, and Jonas Ågrup, CFO, present the report.The presentation can be followed on Youtube via the following link; https://youtube.com/live/LKaop4fJ4Uk. The live presentation will be recorded and is available afterwards via the same link.Participants who wish to ask questions live are asked to pre-register, please send an e-mail to helena.jansson@ratos.com in advance for a personal invitation.The presentation and report will be available on www.ratos.

Wyld Networks receives purchase order of SEK 8.8 million to deliver Satellite IoT connectivity in Oil and Gas sector

A USA based system integrator in the energy sector has placed an order for Wyld Connect modules and terminals for SEK 8.8 million including SEK 0.5 million for initial Wyld Data service.Wyld’s customer manufactures and markets highly specialized sensors and devices for infrastructure monitoring in the oil and gas industry. The company are dedicated to servicing the upstream oil and gas industry through a vast network of engineering, supply chain and manufacturing.   Wyld’s customer provides timely, cost-effective solutions to operators and service companies to ensure maximum

Drilling Update

18 April 2023   IOG plc Drilling update IOG plc ("IOG", or "the Company"), (AIM: IOG.L) provides an update on the drilling of the Blythe H2 well. Having spudded on 5[th] March, the Company estimated that the H2 well was expected to take approximately three months to drill, complete and hook-up, subject to the usual operational risks. The H2 well is being drilled by the Shelf Perseverance jack-up drilling rig under IOG's contract with Shelf Drilling (UK) Ltd ("Shelf") signed in 2020. Petrofac is the Well Operator, as with all previous Saturn Banks development wells. The H2

Annexin reports first imaging-study results in Retinal Vein Occlusion

Annexin Pharmaceuticals AB (“Annexin”) provides an update on its ongoing clinical study in patients with Retinal Vein Occlusion (RVO) using fluorescent labelled ANXV. Images in a case-report of a patient with RVO indicates site-specific accumulation of ANXV in the vessels affected by retinal vein occlusion.Annexin is collaborating with TRACER Europe BV (“TRACER”) and the University Medical Center Groningen (“UMCG”) on an innovative clinical molecular imaging trial. The trial, also referred to as the SIGHT study, uses Annexin’s fluorescently labelled drug candidate ANXV to visualize the

HC Andersen Capital Events 18.04: Meet the top management in GreenMobility & Re-Match

HC Andersen Capital is hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.GreenMobility - Presentation of Q1 2023On 18 April 2023, GreenMobility is expected to announce its Q1 2023 results. In a virtual live event on the same day at 11:00, GreenMobility’s Group CFO Anders Wall will present the financial results and provide an update on the main achievements, where you also can ask questions.   For GreenMobility, 2023 is expected to be a year that is highly affected by the implementation of the new strategy. The new

Inhalation Sciences completes all preparations for FDA BAA dissolution research project

(Stockholm, 18 April 2023) Inhalation Sciences Sweden AB (ISAB) has completed all the required administrative routines necessary to proceed with its FDA BAA (Broad Agency Announcement) contract research project. ISAB expects formal clearance to begin the experimental part of the planned study shortly. The study (contract 75F40122C00197, communicated by ISAB on 15 September 2022) is to evaluate the discriminative power of ISAB’s DissolvIt in vitro dissolution technology.All administrative routines have now been completed, and the formulations to be used in the study are now available onsite

Joseph Bornoff’s Simulations of the Realheart Published in Scientific Reports

Press Release 18 April, 2023 Realheart has several international collaborations with researchers and PhD students to develop the world's first four-chamber heart. One of these is Joseph Bornoff, a PhD student at the University of Bath in the UK. Bornoff has developed an advanced Computational Fluid Dynamics (CFD) model of the Realheart® TAH (Total Artificial Heart) to study blood flow in the pump and optimize its function. The work, co-authored with colleagues at Realheart, has now been published in the Springer Nature journal Scientific Reports.The Realheart model can be simulated

Notice of Annual General Meeting in Epiroc AB

Epiroc AB is hereby convening an Annual General Meeting to be held on Tuesday May 23, 2023, at 5.00 p.m. (CEST) at Filmstaden Sickla, Sickla köpkvarter, Marcusplatsen 19, Nacka, Sweden. Registration starts at 4.30 p.m. Coffee will be served from 3.00 p.m.Please see the full Notice below or visit www.epirocgroup.com/agm. For more information please contact:Karin Larsson, Head of Investor Relations+46 10 755 0106ir@epiroc.comOla Kinnander, Media Relations Manager+46 70 347 2455media@epiroc.comEpiroc is a global productivity partner for mining and infrastructure customers, and

Notice of Annual General Meeting in RugVista Group AB (publ)

The shareholders of RugVista Group AB (publ), Reg. No. 559037-7882, are invited to attend the Annual General Meeting, to be held on Thursday May 25, 2023 at 14:30 at the company’s premises at Frihamnsallén 10 in Malmö, Sweden. Registration for the Annual General Meeting will commence at 14:00. The Board of Directors has decided that shareholders may exercise their voting rights at the Annual General Meeting also by postal voting in accordance with the provisions in RugVista Group AB’s articles of association. Right to participate and notification Participation at the meeting venue

BioStock: Stayble presents additional positive interim data

Just before Easter, Stayble Therapeutics presented positive interim data from 100 patients in the phase IIb study with STA363 for the treatment of degenerative disc disease. The interim analysis shows that the injection treatment is safe and that the pain measurements have a low dispersion, which is beneficial for the final data read-out at the end of the year. BioStock contacted the company’s CSO Anders Lehmann to learn more about the progress of the study.Read the full article at biostock.se: https://www.biostock.se/en/2023/04/stayble-presents-additional-positive-interim-data/ This

Asetek – Update on Q1 2023 Selected Preliminary Financial Figures and Updated Medium-term Ambitions

Aalborg, Denmark - April 18, 2023. Asetek today reports selected preliminary, unaudited, financial figures for the first quarter of 2023. Asetek expects to report revenue of USD 14.7 million for the three months ended March 31, 2023. Gross profit is expected at USD 6.5 million and operating income (EBIT) at USD 1.0 million. The results are primarily a function of revenues on par with the first quarter of 2022, an improved gross margin and significantly lower operating expenses. The gross margin improvement is attributable to, among other factors, a ‘richer’ product mix, increased

Idogen is investigating reverse acquisitions to avoid risk of liquidation

Idogen's work on capitalization has not yet achieved the required result. Idogen is now evaluating, among other things, the possibility of a reverse acquisition. If capital is not added to the company, the board will propose a liquidation.   ”Idogen announced in a press release on April 3 that the funds will last until the end of June. The work on this year's capitalization has not yet obtained  the required result. Idogen is now investigating, among other things, the possibilities for a reverse acquisition (i.e. another company takes over Idogen's listing at the stock market through

Inside information: Tecnotree Corporation announces its intent to issue compulsory convertible debentures valued at EUR 30 million

Tecnotree Corporation inside information 18 April 2023 at 9:01 EETTecnotree Corporation (“Issuer”) declares its intention to launch a transaction involving the issuance of compulsory convertible debenture notes ("Notes") valued at EUR 30 million in total (300 Notes valued at EUR 100,000 each). This initiative aims to bolster Tecnotree's research and development efforts, broaden its current product portfolio, finance mergers and acquisitions. In addition, the funds could be used to repurchase outstanding Tecnotree shares for general treasury, corporate activities, incentive schemes, share

Publishing of Apetit Plc’s Business Review for January-March 2023

Apetit Plc, Press release, on 18 April 2023 at 09:00 a.m.Apetit Plc will publish its Business Review for January-March 2023 on Tuesday 25 April 2023 at 8.30 a.m. A separate press conference in relation to the Business Review will not be arranged. Apetit Plc For further information, please contact: Miika Kemilä, Communications and Sustainability Manager, +358 10 402 4044 Apetit is a food industry company firmly rooted in Finnish primary production. Our operations are based on a unique and sustainable value chain: we create well-being with vegetables by offering tasty food

Katalysen Ventures forms strategic partnership with issuing specialist Nordic Issuing

Katalysen Ventures has initiated a strategic partnership with Sweden-based issuing specialist Nordic Issuing. Through this collaboration, Katalysen Ventures will be able to ensure that its portfolio companies can access a broad range of issuing services, including services related to IPO´s, rights issues, warrant redemptions, public takeover offers and directed issues."We're very excited to be partnering with Nordic Issuing, a team of issuing specialists that we have gotten to know and trust first hand" said Peter Almberg, CEO of Katalysen Ventures. "As our portfolio companies continue to

Poster Presentations at AACR 2023

Faron Pharmaceuticals Oy   ("Faron" or the "Company")   Faron Pharmaceuticals Announces Poster Presentations on Bexmarilimab at the American Association for Cancer Research Annual Meeting 2023   Press Release, April 18, 2023     TURKU, FINLAND / BOSTON, MA: Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces the presentation of two posters at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.   Details of the

There are no items matching the current filter
There are no more items matching the current filter
Back to top